Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
RALEIGH, N.C., April 15, 2016 -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its first quarter 2016 results after the market closes on Wednesday, April 27, 2016. The Company will also host a conference call on Thursday, April 28, 2016 at 9:00 a.m. (ET) to discuss the results with members of the investment community.
To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the United States approximately 10 minutes prior to the call start time. The conference ID for the call is 93641672. An audio replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 within the United States or (404) 537-3406 outside the United States. The replay ID is 93641672.
A live audio broadcast will be available on the investor relations section of the PRA Health Sciences website. Following the teleconference, an audio replay of the call will be available at the same website.
ABOUT PRA HEALTH SCIENCES
PRA is one of the world's leading global contract research organizations, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and approximately 12,000 employees worldwide. Since 2000, PRA has performed approximately 3,300 clinical trials worldwide and has worked on more than 100 marketed drugs across several therapeutic areas. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 60 drugs. To learn more about PRA, please visit www.prahs.com.
INVESTOR INQUIRIES: [email protected] INQUIRIES: Christine Rogers, Manager - Public Relations, Corporate Communications EMAIL: [email protected] PHONE: +1 919.786.8463
